Salipro Biotech Achieves Granted Patent in Japan, Strengthening Global Intellectual Property Portfolio
Tuesday, June 13, 2023
Salipro Biotech AB, a pioneering biotech company focused on the discovery of next-generation therapeutics targeting challenging drug targets, is pleased to announce the issuance of a new patent in Japan for its Salipro® platform technology. This patent, titled "Saposin lipoprotein particles and libraries from crude membranes" (Japanese Patent No. 7149929), further solidifies Salipro Biotech's leading position in membrane protein research and drug discovery.
The granting of this patent in Japan is particularly significant for Salipro Biotech as it strengthens the company's collaborations with top pharmaceutical companies in the country. Salipro Biotech has already established multiple research programs with esteemed partners in Japan to advance drug discovery efforts in the region.
According to Jens Frauenfeld, CEO of Salipro Biotech, "This patent grant in Japan is an important addition to our global intellectual property portfolio, which already includes granted patents in the U.S., EU, and China. Our patented technologies are continuously integrated into our partnered drug discovery programs targeting challenging drug targets such as GPCRs, SLCs, and Ion Channels. This patent further enhances our position as a key holder of a drug discovery platform for the development of next-generation therapeutics."
The patent encompasses Salipro® particles and their application in drug discovery and membrane protein research. It also covers Salipro Biotech's innovative method of directly extracting membrane proteins (DirectMX®) from cells or crude membranes to facilitate drug development for challenging drug targets. Additionally, the patent includes the generation of Salipro® libraries representing the membrane proteome. By expanding its intellectual property portfolio, this patent strengthens Salipro Biotech's value proposition for collaborations with pharmaceutical companies and its internal pipeline.
